PIK3CA and neoplasm: Moreover, the drug combination inhibited tumor growth synergistically in CRCs with a PIK3CA helical domain mutation (Figure S7h), but had only an additive effect on CRCs with either WT PIK3CA or a PIK3CA H1047R mutation (Figure S7h).